A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer

Research output: Contribution to journalReview article

19 Scopus citations

Abstract

Advanced non-small-cell lung cancer (NSCLC) remains a major global health problem. Although the reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib improves survival in patients with relapsed and recurrent NSCLC, significant limitations exist, including the restriction of clinical efficacy to a small patient subset, poor survival rates, and the development of resistance. Irreversible inhibitors of EGFR and HER2 are novel agents in clinical development that might have the potential to prevent and overcome acquired resistance to first-generation EGFR inhibitors.

Original languageEnglish
Pages (from-to)8-12
Number of pages5
JournalClinical Lung Cancer
Volume11
Issue number1
DOIs
StatePublished - 2010

Keywords

  • BIBW 2992
  • ErbB
  • Erlotinib
  • Gefitinib
  • HKI-272
  • Receptor tyrosine kinase

Fingerprint Dive into the research topics of 'A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this